Navigation Links
Medifast Program Combined with Appetite Suppressants Proven to Yield Double the Weight Loss Compared to Suppressants Alone
Date:7/31/2008

OWINGS MILLS, Md., July 31 /PRNewswire-FirstCall/ -- Medifast, Inc. (NYSE: MED) today announced that a recent study published in 'The Journal of Eating and Weight Disorders' shows that individuals taking appetite suppressant medications can expect double the weight loss when they combine their drug therapy with a medical protocol using Medifast Meal Replacement Supplements.

The 52-week study, conducted by researchers at the University of Missouri-Kansas City School of Medicine and Baylor College of Medicine shows that participants who consistently used Medifast Meal Replacements along with pharmacotherapy lost an average of 14% of their body weight in one year. This amount of weight loss is approximately double what is seen in university studies of obesity medications alone over the same time frame. In the study, more than 80% of the participants lost at least 5% of their body weight, which is more than double that found for other structured commercial weight loss programs.

"The results of studies featuring Medifast Meal Replacements are superior to those typically observed for other obesity interventions including weight loss medications and other commercial weight loss plans," says Lisa M. Davis, Ph.D., PA-C, C.N.S., L.D.N., Director of Research and Development, Medifast, Inc. "This suggests that comprehensive weight control programs featuring Medifast provide a unique solution for weight control."

While the Company does not advocate the use of weight loss drugs, Medifast does recognize that diet pills are part of the weight loss landscape now and are likely to remain so in the future. Medifast is a proven weight control program in and of itself, and has now been shown to double the results of comprehensive weight control programs employing appetite suppressant medications.

Medifast will continually participate in studies in the future, which will add even more credibility to the Brand and its Programs. For more than 25 years Medifast has been prescribed by practitioners as a safe and effective program that has been clinically proven to yield significant weight loss of 2-5 pounds per week.

Since 1980, 15,000 physicians from across the country have trusted Medifast to provide their patients with the highest quality, nutritious weight loss and disease management solutions.

MED-G

About Medifast:

Medifast (NYSE: MED) is the leading easy-to-use, clinically proven portion-controlled weight loss program. Medifast has been recommended by 15,000 physicians and used by over one million customers. Medifast is committed to enriching lives by providing innovative choices for lasting health. Medifast programs have been proven effective through studies by major university teaching hospitals. The company sells its products and programs via four unique distribution channels: 1) the web and national call centers, 2) the Take Shape For Life direct-selling division, a network of health coaches, 3) medically supervised Medifast Weight Control Centers, and 4) national network of physicians. Medifast was founded in 1980 and is located in Owings Mills, Maryland. For more information, log onto http://www.choosemedifast.com.


'/>"/>
SOURCE Medifast, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Medifast Announces Winners of Mother-Daughter Challenge
2. Medifast, Inc. Announces Support for Microsoft HealthVault
3. Medifast Announces Updated Full Year 2007 Guidance
4. Medifast Announces Third-Quarter 2007 Results
5. Medifast, Inc. Receives Approval to Sell Medifast Weight Control Centers Franchises in Seven Additional States
6. Medifast, Inc. to Unveil New Advertising Campaign Featuring Genie Francis and New Web Features in Early 2008
7. Medifast, Inc. Director of Research & Development Co-Authors Health Book
8. Medifast Receives Notice Regarding NYSE Listing
9. Medifast Offers Stranded Pure Weight Loss Clients Unique Options
10. Medifast Offers 5 Heart Healthy Tips in Recognition of Fridays National Wear Red Day
11. Medifast Franchise Systems Sells First Territory in Baltimore
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... ... PawPaws brand pet supplements owned by Whole Health Supply is ... of felines. The formula is all-natural and is made from Chinese herbs that have ... Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root Extract ...
(Date:6/25/2016)... ... 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to a ... new, often overlooked aspect of head lice: the parasite’s ability to live away from a ... occurrence, but a necessary one in the event that lice have simply gotten out of ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... On Friday, ... presented a Bronze Wellness at Work award to iHire in recognition of their exemplary ... part of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI ...
(Date:6/24/2016)... ... , ... Marcy was in a crisis. Her son James, eight, was out of control. Prone ... physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If ... at my other children and say he was going to kill them. If we ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, ... minimum wage raise to $12 an hour by 2020 and then adjusting it yearly to ... value of the minimum wage, assure the wage floor does not erode again, and make ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
(Date:6/23/2016)... June 23, 2016 Capricor ... ), a biotechnology company focused on the discovery, ... that patient enrollment in its ongoing randomized HOPE-Duchenne ... exceeded 50% of its 24-patient target. Capricor expects ... third quarter of 2016, and to report top ...
Breaking Medicine Technology: